Dr. Fred R. Hirsch on Unmet Needs in Lung Cancer

Zipalertinib demonstrated efficacy in pretreated NSCLC with EGFR exon 20 insertion mutations, meeting the primary endpoint of ORR in the REZILIENT1 study.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

While the phase 2 trial did not meet its primary endpoint, it demonstrated that SBRT plus concurrent radiotherapy yielded better results than those observed in previous studies.

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for those with advanced, treatment-naïve disease.